Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cytokine Release Syndrome Clear all

Conditions: Uveal Melanoma, Metastatic
Interventions: Dexamethasone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: B-Cell Non-Hodgkin Lymphoma
Interventions: Anakinra, X-Ray Imaging, Positron Emission Tomography, Computed Tomography, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture, Biospecimen Collection; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
Interventions: Anakinra; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions: Anakinra, 0.9% Saline; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemophagocytic Lymphohistiocytosis
Interventions: tocilizumab; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Months to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Naresh Bumma; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COVID-19, Cytokine Storm
Interventions: Fluoxetine; Drug
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions: Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin; Drug
Lead sponsor: Taylor Brooks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions: iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Myeloma
Interventions: TempShield Continuous Temperature Monitoring, Standard of Care; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions: Mesenchymal stromal cells, Placebo; Biological · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions: Lenzilumab, Standard of Care; Biological · Drug
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more

Conditions: Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions: Best Practice, Low Dose Radiation Therapy; Other · Radiation
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: COVID-19
Interventions: Prazosin, Standard of care; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Covid19, Cytokine Storm, Inflammation
Interventions: Splenic ultrasound; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Covid19, Cytokine Release Syndrome
Interventions: dapansutrile capsules, placebo capsules; Drug
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more

Conditions: Cytokine Release Syndrome
Interventions: Itacitinib, Immune effector cell therapy, Placebo, Yescarta; Drug · Biological
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more

Conditions: Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions: TempTraq, VitalTraq; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19
Interventions: Etoposide; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions: Siltuximab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cytokine Release Syndrome, COVID19
Interventions: Therapeutic Plasma Exchange, Ruxolitinib; Procedure · Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 12 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
Interventions: APRV, Conventional MV; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: Cyclosporine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cytokine Release Syndrome
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee

Search by objective public record fields.

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Anakinra, COVID-19, Cytokine Storm

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

UNITE Study (UMN-GE) for COVID-19

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Etoposide in Patients With COVID-19 Infection

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Airway Pressure Release Ventilation in Acute Lung Injury

Cyclosporine in Patients With Moderate COVID-19

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects